Investor Centre

Pharmaceutical company Pharmaxis (ASX:PXS) is pleased to announce that it has appointed PharmaSwiss SA, a division of Valeant Pharmaceuticals International, Inc, as distributor for Bronchitol® in Poland and ten other Eastern European countries.

Headquartered in Switzerland, PharmaSwiss operates in 17 Central and Eastern European countries with regional expertise across regulatory affairs, compliance, sales, marketing and distribution.

Pharmaxis CEO Mr Gary Phillips said, “Pharmaxis is moving swiftly in executing plans for the continued commercialisation of Bronchitol. With more than 6,000 cystic fibrosis patients, Poland is a solid market where our European Union approval applies. PharmaSwiss is well equipped to support us with a firm presence in Poland and other Eastern European countries.”